NAN – Morgans rates the stock as Add

As part of a trading update, management at Nanosonics anticipates the consensus estimate for FY22 revenue will be met. Morgans points out the transition to a direct sales model with GE is on-track.

The sales and clinical applications team has been expanded to meet the end of June transition-completion date. The broker maintains its Add rating and $5.43 target price.

Sector: Health Care Equipment & Services.


Target price is $5.43.Current Price is $3.87. Difference: $1.56 – (brackets indicate current price is over target). If NAN meets the Morgans target it will return approximately 29% (excluding dividends, fees and charges – negative figures indicate an expected loss).



About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →